For #Investors: We’ll be sharing our 9M and Q3 2026 performance update at 07:00 GMT on 30 October 2026. An accompanying webcast for investors and analysts will take place at 14:30 GMT. Register to attend virtually here: learn.az/6016BHkNas $AZN

🧬Today marks the opening of our new global R&D centre in Cambridge, Massachusetts, US. Bringing together exceptional talent and cutting-edge technologies to help accelerate scientific discovery and advance the next generation of medicines. Learn more: learn.az/6016BGLoRQ $AZN #WhatScienceCanDo

At #ClimateWeekNYC, we shared how partnership is critical for healthier people, health systems and the planet. Highlights included: our $100m Young Health Programme commitment, a new tool that models the environmental impact of care pathways and the European Network on Climate and Health Education reaching 6,000 medical students. Thanks to colleagues, partners and young leaders who made this progress possible.

We’re investing more than $100m in our Young Health Programme 2010 to 2030, in partnership with @UNICEF and 60 NGO partners. By 2030, the programme aims to reach 10m more young people in underserved communities and train 800,000 youth advocates. Learn more: learn.az/6016BGdXUg #YoungHealthProgramme

Patient care delivery accounts for around 40% of emissions from the healthcare sector. Today we're launching CARESA, a free tool that helps health systems estimate the environmental footprint of care pathways and explore opportunities for more sustainable care🌍 🔗learn.az/6013BGjHml

Named #5 in TIME’s World’s Best Companies and ranked #1 in our industry 🌍 Behind this recognition: 96,000+ colleagues, partners and suppliers working together for people, society and the planet. learn.az/6013BGKaxt #WhatScienceCanDo #TIME #WorldsBestCompanies

32 young leaders from 24 countries. One shared goal: better health. Meet our 2026 Young Health Programme Impact Fellows and Scholars taking action on health equity, health systems resilience and climate and nature. With @OneYoungWorld and @YouthAssembly. #YoungHealthProgramme

Since our FY 2025 results, our pipeline has delivered 6 key positive Phase III programmes and 8 first approvals in major markets. Learn more: learn.az/6012BEvvGp #AZN #FinancialResults $AZN

In H1 2026, Core EPS increased 11% reflecting strong commercial execution and confidence in our long-term outlook. Learn more: learn.az/6012BEvvGp #AZN #FinancialResults $AZN

Our H1 2026 results demonstrate that we are on track to deliver our $80bn Total Revenue ambition and drive growth beyond 2030. Learn more: learn.az/6012BEvvGp #AZN #FinancialResults $AZN